Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Assets (2016 - 2025)

Historic Assets for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $288.3 million.

  • Voyager Therapeutics' Assets fell 3232.79% to $288.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 3232.79%. This contributed to the annual value of $393.0 million for FY2024, which is 1189.05% up from last year.
  • Per Voyager Therapeutics' latest filing, its Assets stood at $288.3 million for Q3 2025, which was down 3232.79% from $322.1 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Assets ranged from a high of $469.6 million in Q1 2024 and a low of $159.4 million during Q4 2022
  • Moreover, its 5-year median value for Assets was $294.7 million (2023), whereas its average is $292.9 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Assets soared by 12043.79% in 2023, and later tumbled by 3232.79% in 2025.
  • Voyager Therapeutics' Assets (Quarter) stood at $193.9 million in 2021, then dropped by 17.8% to $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then increased by 11.89% to $393.0 million in 2024, then fell by 26.65% to $288.3 million in 2025.
  • Its last three reported values are $288.3 million in Q3 2025, $322.1 million for Q2 2025, and $353.2 million during Q1 2025.